A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules.

This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.
Head and Neck Cancer|Cervical Cancer|Non-small Cell Carcinoma|Melanoma|Ovarian Cancer|Anogenital Cancers|HPV - Anogenital Human Papilloma Virus Infection|HPV-Related Cervical Carcinoma|HPV-Related Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Malignancy|HPV-Related Adenocarcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Associated Vaginal Adenocarcinoma|HPV-Related Endocervical Adenocarcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Verrucous Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV Positive Rectal Squamous Cell Carcinoma
BIOLOGICAL: TSC-204-A0201|BIOLOGICAL: TSC-204-C0702|BIOLOGICAL: TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-204-C0702|BIOLOGICAL: TSC-204-A0201 + TSC-200-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-203-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-203-A0201|BIOLOGICAL: TSC-204-A0101|BIOLOGICAL: TSC-201-B0702|BIOLOGICAL: TSC-204-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-204-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-204-C0702 + TSC-204-A0101|BIOLOGICAL: TSC-204-C0702 + TSC-201-B0702|BIOLOGICAL: TSC-200-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-200-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-203-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-203-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-202-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-202-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-203-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-A0101 + TSC-202-A0201|BIOLOGICAL: TSC-201-B0702 + TSC-202-A0201
Evaluate the safety of monotherapy and T- Plex combination TCR-Ts, Number of subjects with dose limiting toxicities (DLT), 28 days|Determine the recommended phase 2 dose of monotherapy and T- Plex combination TCR-Ts, Frequency and severity of DLTs, AEs and SAEs, Up to 12 months
Investigate preliminary anti-tumor activity of monotherapy and T- Plex combination TCR-Ts, Response Evaluation Criteria In Solid Tumors RECIST 1.1, Up to 12 months|Investigate the feasibility of repeat dosing of monotherapy and T- Plex combination TCR-Ts, Frequency and severity of DLTs, AEs and SAEs, Up to 12 months
To measure the persistence of T-Plex TCR-T cells in the peripheral blood with single and repeat doses, Percentage of TCR-T cells in the peripheral blood after single and repeat doses, Up to 24 months|To measure the infiltration of T-Plex TCR-T cells into tumors in post-treatment biopsies, Percentage of TCR-T cells in the tumor after single and repeat doses, Up to 24 months|To measure the immune activation markers in the tumor after single and repeated doses, Status of immune activation markers in the tumor after single and repeat doses, Up to 24 months
Participants will be screened in a separate screening study, TSCAN-003 (NCT05812027), to assess their HLA type, tumor-associated antigen (TAA) expression and loss of heterozygosity (LOH) status. The results of these tests will be used to determine initial eligibility in this study.

Depending on the genetic type, participants will be assigned to one of the following study groups:

Monotherapy:

* COHORT A: TSC-204-A0201 targeting MAGE-A1 on HLA-A\*02:01
* COHORT B: TSC-204-C0702 targeting MAGE-A1 on HLA-C\*07:02
* COHORT C: TSC-200-A0201 targeting HPV16 E7 on HLA-A\*02:01
* COHORT D: TSC-203-A0201 targeting PRAME on HLA-A\*02:01
* COHORT E: TSC-204-A0101 targeting MAGE-A1 on HLA-A\*01:01
* COHORT F: TSC-201-B0702 targeting MAGE-C2 on HLA-B\*07:02
* COHORT G: TSC-202-A0201 targeting MAGE-A4 on HLA-A\*02:01

T-Plex Combination:

* COHORT AB: TSC-204-A0201 + TSC-204-C0702
* COHORT AC: TSC-204-A0201 + TSC-200-A0201
* COHORT AD: TSC-204-A0201 + TSC-203-A0201
* COHORT AE: TSC-204-A0201 + TSC-204-A0101
* COHORT AF: TSC-204-A0201 + TSC-201-B0702
* COHORT BC: TSC-204-C0702 + TSC-200-A0201
* COHORT BD: TSC-204-C0702 + TSC-203-A0201
* COHORT BE: TSC-204-C0702 + TSC-204-A0101
* COHORT BF: TSC-204-C0702 + TSC-201-B0702
* COHORT CD: TSC-200-A0201 + TSC-203-A0201
* COHORT CE: TSC-200-A0201 + TSC-204-A0101
* COHORT CF: TSC-200-A0201 + TSC-201-B0702
* COHORT DE: TSC-203-A0201 + TSC-204-A0101
* COHORT DF: TSC-203-A0201 + TSC-201-B0702
* COHORT EF: TSC-204-A0101 + TSC-201-B0702
* COHORT AG: TSC-204-A0201 + TSC-202-A0201
* COHORT BG: TSC-204-C0702 + TSC-202-A0201
* COHORT CG: TSC-200-A0201 + TSC-202-A0201
* COHORT DG: TSC-203-A0201 + TSC-202-A0201
* COHORT EG: TSC-204-A0101 + TSC-202-A0201
* COHORT FG: TSC-201-B0702 + TSC-202-A0201

Participants will undergo leukapheresis to collect cells to manufacture the TCR-T products. They will then undergo lymphodepletion and receive one or two doses of the TCR-T cell therapy product as a monotherapy or part of a combination of TCR-Ts (referred to as T-Plex combinations in this study).